WAGSTAFFE, H. R.; SUSANNINI, G.; THIEBAUT, Rodolphe; RICHERT, Laura; LEVY, Y.; BOCKSTAL, V.; STOOP, J. N.; LUHN, K.; DOUOGUIH, M.; RILEY, E. M.; LACABARATZ, C.; GOODIER, M. R.

doi:10.1038/s41541-021-00280-0

Statistics In System biology and Translational Medicine [SISTM]
Bordeaux population health [BPH]

Langue

Article de revue

Ce document a été publié dans

NPJ vaccines. 2021-01-29, vol. 6, n° 1, p. 19

Résumé en anglais

Natural killer (NK) cells are implicated among immune effectors after vaccination against viral pathogens, including Ebola virus. The two-dose heterologous Ebola virus vaccine regimen, adenovirus type 26.ZEBOV followed by modified vaccinia Ankara-BN-Filo (EBOVAC2 consortium, EU Innovative Medicines Initiative), induces NK cell activation and anti-Ebola glycoprotein (GP) antibody-dependent NK cell activation post-dose 1, which is further elevated post-dose 2. Here, in a multicentre, phase 2 clinical trial (EBL2001), we demonstrate durable ex vivo NK cell activation 180 days after dose 2, with responses enriched in CD56(bright) NK cells. In vitro antibody-dependent responses to immobilised Ebola GP increased after dose 1, and remained elevated compared to pre-vaccination levels in serum collected 180 days later. Peak NK cell responses were observed post-dose 2 and NK cell IFN-γ responses remained significantly elevated at 180 days post-dose 2. Individual variation in NK cell responses were influenced by both anti-Ebola GP antibody concentrations and intrinsic interindividual differences in NK cell functional capacity. In summary, this study demonstrates durable NK cell responses after Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccination and could inform the immunological evaluation of future iterations of the vaccine regimen and vaccination schedules.< Réduire

URI

https://oskar-bordeaux.fr/handle/20.500.12278/26406

DOI

http://dx.doi.org/10.1038/s41541-021-00280-0

Unités de recherche

Bordeaux Population Health Research Center (BPH) - UMR 1219

Voir/Ouvrir

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Durable natural killer cell responses after heterologous two-dose Ebola vaccination

Langue

Ce document a été publié dans

Résumé en anglais

URI

DOI

Unités de recherche